CELLDEX/LUDWIG INST. FORM RESEARCH COLLABORATION.Celldex Therapeutics, Inc. and the international Ludwig Institute for Cancer Research The Ludwig Institute for Cancer Research (LICR) is a global non-profit medical research institute that undertakes laboratory and clinical research into cancer, conducting and sponsoring its own early-phase clinical trials to investigate its discoveries. (LICR LICR Ludwig Institute for Cancer Research ) have announced a multi-year clinical research collaboration focusing on a series of tumor-associated antigens (TAAs) for use in Celldex's Antigen Presenting Cell (APC (1) (American Power Conversion Corporation, West Kingston, RI, www.apcc.com) The leading manufacturer of UPS systems and surge suppressors, founded in 1981 by Rodger Dowdell, Neil Rasmussen and Emanual Landsman, three electronic power engineers who had worked at MIT. ) Targeting Technology. These antigens, previously identified and characterized immunologically by LICR, will add substantially to new Celldex development programs for a range of cancer types. Three of these antigens (NY-ESO-1, MAGE3, and MelanA) are being studied in non-small cell lung, ovarian, and bladder cancers, as well as melanoma, in an extended series of Phase I/II programs conducted by the LICR and its collaborators.
The collaboration will encompass the development of next-generation immunotherapies using Celldex's proprietary APC targeting monoclonal antibodies and the Ludwig TAAs. These development candidates will be available to LICR for evaluation within the Cancer Vaccine Collaborative (CVC See CSC. ) worldwide clinical research network, a collaboration between the LICR and the leading cancer charity, the New York-based Cancer Research Institute.
"The Celldex technology is a novel approach to inducing a patient's immune system immune system
Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to fight cancer," said Jonathan C.A. Skipper, Ph.D., Executive Director for Intellectual Property & Technology Licensing at the Ludwig Institute. "This system has the potential to deliver TAAs precisely to the right cells, in contrast to other TAA TAA - Track Average Amplitude delivery technologies. The CVC is very much looking forward to exploring this promising TAA delivery approach in its early-phase clinic trials."
"We are pleased to announce this agreement with the Ludwig Institute, an acknowledged academic leader in the field of cancer immunotherapy, as a key addition to our cancer development programs," said Robert Burns, Ph.D., president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Celldex Therapeutics. "With the licensing of this important portfolio of clinically-validated cancer antigens, we strengthen our commitment to developing innovative immunotherapies against a wide variety of oncology targets, employing our unique APC targeted delivery methodology."
About the Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research (LICR) is the largest international academic institute dedicated to understanding and controlling cancer. Headquartered in New York, and with one Center for Clinical Sciences and nine Branches in seven countries, the scientific network that is LICR spans the globe. LICR has developed an impressive portfolio of reagents, knowledge, expertise, and intellectual property, and has also assembled the personnel, facilities, and practices necessary to patent, clinically evaluate, license, and thus translate, the most promising aspects of its own laboratory research into cancer therapies.
About the Cancer Research Institute
The Cancer Research Institute (CRI CRI
constant-rate infusion. ) is a non-profit organization that funds research aimed at furthering the development of immunological approaches to the diagnosis, treatment, and prevention of cancer. CRI's research programs are designed to recognize and support those researchers around the world who are focused on this area. Today, CRI provides funding at every level of scientific inquiry, from coordinated clinical trials to the most basic research, and supports scientists at all career levels.
About the APC Targeting Technology
The foundation of Celldex Therapeutics' Antigen Presenting Cell (APC) Targeting TechnologyT is the ability of the company's proprietary antibodies to deliver agents to specific cellular components of the immune system. In particular, Celldex has developed antibodies that possess unique characteristics for delivering antigens directly to professional APCs, dendritic cells and macrophages Macrophages
White blood cells whose job is to destroy invading microorganisms. Listeria monocytogenes avoids being killed and can multiply within the macrophage. that we believe will generate rapid and heightened immune responses. By effectively targeting antigens (or other agents) to these specialized cells of the immune system, Celldex's product candidates can transform even weakly immunogenic im·mu·no·gen·ic
Producing an immune response.
producing immunity; evoking an immune response. antigens into effective targets for immunotherapy, and circumvent the need for individualized ex vivo dendritic cell manipulation.
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a biotechnology company focused on developing fully human antibody-based products that target and stimulate the body's immune system for the treatment of cancer, infectious and autoimmune diseases. The company's lead product, CDX-110, is scheduled to have entered a definitive Phase 2/3 clinical trial for the treatment of newly diagnosed glioblastoma glioblastoma /glio·blas·to·ma/ (gli?o-blas-to´mah) any malignant astrocytoma.
glioblastoma multifor´me by early 2007. Celldex has three product candidates already in or about to enter clinical development targeting multiple cancers as well as Hepatitis B. Four additional product candidates are in preclinical development for cancer and autoimmune disease. Celldex's proprietary technology platform uses fully human monoclonal antibodies administered directly to patients to target and stimulate dendritic cells - key cells within the immune system. Celldex was formed in 2004 as a spin-out from Medarex, Inc. (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :MEDX). The company is headquartered in Phillipsburg, New Jersey Phillipsburg, known locally as P'burg, is a town in Warren County, New Jersey, in the United States. As of the United States 2000 Census, the town population was 15,166. and also has R&D operations in Cambridge, UK.
For more information, call 212/477-9007, ext. 33.